Trial Profile
Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Nelarabine (Primary) ; Cyclophosphamide; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Filgrastim; Mercaptopurine; Mesna; Methotrexate; Pegaspargase; Prednisone; Venetoclax; Vincristine
- Indications Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
- Focus Therapeutic Use
- 01 Sep 2023 Planned End Date changed from 31 Oct 2023 to 31 Oct 2024.
- 01 Sep 2023 Planned primary completion date changed from 31 Oct 2023 to 31 Oct 2024.
- 11 Jan 2023 Planned End Date changed from 31 Oct 2022 to 31 Oct 2023.